| P410 | MV-626, a potent and selective inhibitor of ENPP1 enhances STING activation and augments T-cell mediated anti-tumor activity in vivo | Jason R. Baird, PhD; Gregory N. Dietsch, PhD, DABT; Vincent Florio, PhD; Michael Gallatin, PhD; Clayton D. Knox, MD; Joshua Odingo, PhD; Marka R. Crittenden, MD, PhD; Michael J. Gough, PhD | Cytokine; Immune adjuvant; Radiotherapy; Tumor microenvironment |
| P411 | An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure | Matthew J. Bernett, PhD; Rajat Varma, PhD; Christine Bonzon, PhD; Liz Bogaert, PhD; Rumana Rashid, PhD; Ke Liu, PhD; Irene Leung, PhD; Suzanne Schubbert, PhD; Sung-Hyung Lee, PhD; Daniel C. Kirouac, PhD; Fei Hua, PhD; Nicole Rodriguez, PhD; Yoon Kim, PhD; Kendra N. Avery, PhD; Connie Ardila; Nargess Hassanzadeh-Kiabi, PhD; Umesh Muchhal, PhD; Seung Chu, PhD; Gregory L. Moore, PhD; John R. Desjarlais, PhD | Cytokine; NK/NK T cell; Solid tumors; T cell |
| P412 | Tumor cell-intrinsic defects in STING pathway signaling | Blake Flood, BS; Leticia Corrales; Thomas F. Gajewski, MD, PhD | Cytokine; Gene expression; Tumor microenvironment |
| P413 | The FAP-IL2v immunocytokine is a versatile combination partner for cancer immunotherapy | Valeria Nicolini; Inja Waldhauer; Anne Freimoser-Grundschober; Federica Cavallo; Sara Colombetti; Marina Bacac; Gonzalo Acuna; Jehad Charo, PhD; Stefan Evers, PhD; Volker Teichgraeber, MD; Pablo Umana, PhD; Christian Klein, Dr rer nat; Christian Klein, Dr rer nat; Christian Klein, Dr rer nat; | Antibody; Checkpoint blockade; Cytokine; T cell; Targeted therapy; Tumor stroma |
| P414 | Efficacy of anti-PD-L1/IL-15 fusion protein in multiple tumor models | Stella Martomo, PhD; Dan Lu, MA; Zhanna Polonskaya; Xenia Luna; Kevin McCracken; Jeegar Patel | Antibody; Checkpoint blockade; Cytokine; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs) |
| P415 | Preclinical characterization of IL-2 Superkines engineered with biased CD8+ T cell stimulating properties | Fahar Merchant, PhD; Shafique Fidai; Aaron M. Ring | Antibody; Cytokine; Immune suppression; Immune toxicity; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P416 | Short-course IL-15 given as a continuous infusion leads to massive expansion of NK cells: Implications for combination therapy with anti-tumor antibodies | Milos Miljkovic, MD, MSc; Sigrid Dubois, PhD; Thomas A. Fleisher, MD; Jennifer H. Albert, RN; Thomas A. Waldmann, MD; Kevin C. Conlon, MD; | Antibody; Clinical study; Clinical trial; Cytokine; NK/NK T cell; Solid tumors; T cell |
| P417 | SYTX80-013-A: an engineered IL-2 for the treatment of solid tumors with superior pre-clinical efficacy and safety evidence | Marcos E. Milla, PhD; Jerod L. Ptacin, PhD; Carolina E. Caffaro; Hans R. Aerni, PhD; Lina Ma; Kristine M. San Jose; Michael J. Pena; Robert W. Herman; Yelena Pavlova; David B. Chen; Laura K. Shawver; Lilia K. Koriazova; Ingrid B. Joseph | Cytokine; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P418 | Pre-clinical investigation of NKTR-255, a polymer-conjugated human IL-15 with a potent NK cell dependent anti-tumor efficacy | Takahiro Miyazaki, MS; Murali K. Addepalli, PhD; Arunasree Lanka, PhD; Amol Murkar, MSc; Ravikumar Nutakki; Palakshi Obalapur, PhD; Peiwen Kuo, PhD; Phi Quach, BS PhD; Mekhala Maiti, PhD; Laurie VanderVeen, PhD; Ping Zhang, MS PhD; Loui Madakamutil; Jonathan Zalevsky, PhD | Cytokine; Immune monitoring; NK/NK T cell |
| P419 | NKTR-214 in combination with radiation produces a potent in situ vaccine in the syngeneic B78 melanoma model. | Alexander Pieper, B.S.; Alexander L. Rakhmilevich, MD, PhD; Jacob Slowinski, Mr.; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Zachary S. Morris, MD, PhD; Deborah Charych, PhD; Paul M. Sondel, MD, PhD | Cytokine; NK/NK T cell; Solid tumors; T cell; Vaccine |
| P420 | Outpatient staccato pulse intravenous Interleukin-2 in metastatic melanoma | Walter S. Quan, Jr., MD; Leah I. Gutierrez, RN BSN; Erin Johnson; Francine M. Quan, RN MSN OCN | Adoptive immunotherapy; Cytokine |
| P421 | Combination of Pegilodecakin (AM0010) with Docetaxel improves immune cell-mediated anti-tumor response in mouse 4T1 tumor model | Navneet Ratti, BS, MBA; Rakesh Verma, PhD; Martin Oft, MD | Chemotherapy; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P422 | A polymer-associated human IL-15 (NKTR-255) has optimized biological activity and unique mechanisms of action on CD8 T Cells and NK Cells | Tanya O. Robinson, PhD; Shweta M. Hegde; Sarai C. Rivas, BS; Takahiro Miyazaki, MS; Kimberly S. Schluns, PhD | Cytokine; NK/NK T cell; T cell |
| P423 | Safety, pharmacokinetics and pharmacodynamic effects of ALKS 4230 in patients with advanced solid tumors from the ongoing dose escalation portion of a first in human (FIH) study | Ulka Vaishampayan, MD; Vamsidhar Velcheti, MD FACP; David F. McDermott, MD; Mayer N. Fishman, MD, PhD; Chris J. Hoimes, MD; Daniel C. Cho, MD; Lei Sun, Ph.D; Juan C. Alvarez, PhD; Heather C. Losey, PhD; Rose Marino, MD; Emily L. Putiri, PhD; Sean Rossi; Lisa Von Moltke, MD; William J. Slichenmyer, MD; Marc S. Ernstoff, MD | Biomarkers; Clinical study; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P424 | NKTR-214, an engineered IL-2, selectively depletes intratumoral Tregs and expands immunotherapy-induced effector T cell responses | Meenu Sharma, PhD; Hiep Khong, PhD; Faisal Fa'ak, MD; Brent C. Chesson; Barbara M. Pazdrak; Laura Maria S Kahn; Louise Janssen, MSc; Uddalak Bharadwaj; Binisha Karki; Zhilan Xiao, MD; Yared Hailemichael, PhD; Manisha Singh, PhD; Christina Vianden, MSc; David Tweardy; Salah Eddine Bentebibel; Cara Haymaker, PhD; Chantale Bernatchez; Adi Diab, MD; Ute Hoch, PhD; Jonathan Zalevsky, PhD; Willem W. Overwijk, PhD; | Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); Vaccine |
| P425 | Pharmacokinetics and pharmacodynamic effects of ALKS 4230, an investigational immunotherapeutic agent, in cynomolgus monkeys after intravenous and subcutaneous administration | Lei Sun, Ph.D; Jared Lopes, PhD; Heather L. Flick, MS; Erin A. Murphy, MS; Heather C. Losey, PhD | Biomarkers; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| O30 | First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers | Timothy A. Yap, MD; Capucine Baldini, MD; Christophe Massard, MD, PhD; Ivelina Gueorguieva, PhD; Yumin Zhao, PhD; Shelly L. Schmidt; Michael Man, PhD; Shawn T. Estrem, PhD; Karim A. Benhadji, MD; Maria Vieito, MD | Clinical trial; Cytokine; Inflammation; Solid tumors; Targeted therapy; Tumor microenvironment |
| O31 | Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma | Joanna Pucilowska, PhD; Venkatesh Rajamanickam; Nicole Moxon, RN; Katherine Sanchez, MD; Monil Shah, PharmD; James Imatani, MD; Shaghayegh Aliabadi-Wahle, MD; Maritza Martel, MD; Alison K. Conlin, MD; James E. Egan, PhD; David B. Page, MD | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Gene expression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O32 | Decoy-resistant Interleukin-18 overcomes the soluble immune checkpoint IL-18BP to unlock a potent immunotherapeutic cytokine pathway | Ting Zhou; William Damsky, MD, PhD; Karen P. Hartmann, MS; Suzanne Fischer, BS; Marcus W. Bosenberg, MD, PhD; Aaron M. Ring | Checkpoint blockade; Costimulation; Cytokine; Gene expression; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O33 | Adaptive plasticity of IL10+ and IL35+ regulatory T cells and their cooperative regulation of anti-tumor immunity | Hiroshi Yano, BS; Deepali V. Sawant, PhD; Maria Chikina, PhD; Qianxia Zhang, PhD; Zhe Sun; Tao Sun; Wei Chen; Creg Workman, PhD; Dario A. Vignali, PhD; | Bioinformatics; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O34 | Next-generation retroviral vector with membrane-anchored IL-12 to improve adoptive T cell immunotherapy and enhance its safety | Ling Zhang; John Davies; Carylinda Serna; Zhiya Yu; Nicholas P. Restifo, MD; Steven A. Rosenberg, MD, PhD; Christian S. Hinrichs, MD | Adoptive immunotherapy; Cytokine; T cell |
